Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03235167

Enrollment

100

Registered

2017-08-01

Start date

2017-10-31

Completion date

2022-10-31

Last updated

2017-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA

Interventions

DRUGCpG DNA

CpG DNA concentrate

PROCEDUREtranscatheter arterial chemoembolization

transcatheter arterial chemoembolization (TACE) therapy for liver cancer

DRUGPlacebo - Concentrate

CpG DNA vehicle

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

55 Years to 75 Years

Healthy volunteers

Inclusion criteria

* TNM (tumor node metastasis ) staging with non distant metastasis; no other tumors

Exclusion criteria

* having received previous treatment for liver cancer

Design outcomes

Primary

Measure	Time frame
survival time	5 years
metastasis free survival time	5 years

Contacts

Primary Contacthaoren wang

haoren_wang@yahoo.com86-041162893507

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026